FLT3: ITDoes matter in leukemia

M. Levis; D. Small

doi:10.1038/sj.leu.2403099

FLT3: ITDoes matter in leukemia

M. Levis, D. Small

School of Medicine

Research output: Contribution to journal › Review article › peer-review

350 Scopus citations

Abstract

FMS-like tyrosine kinase-3 (FLT3), a receptor tyrosine kinase, is important for the development of the hematopoietic and immune systems. Activating mutations of FLT3 are now recognized as the most common molecular abnormality in acute myeloid leukemia, and FLT3 mutations may play a role in other hematologic malignancies as well. The poor prognosis of patients harboring these mutations renders FLT3 an obvious target of therapy. This review summarizes the data on the molecular biology and clinical impact of FLT3 mutations, as well as the therapeutic potential of several small-molecule FLT3 inhibitors currently in development.

Original language	English (US)
Pages (from-to)	1738-1752
Number of pages	15
Journal	Leukemia
Volume	17
Issue number	9
DOIs	https://doi.org/10.1038/sj.leu.2403099
State	Published - Sep 1 2003

Keywords

AML
FLT3
ITD
Receptor tyrosine kinase
Tyrosine kinase inhibitor

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/sj.leu.2403099

Cite this

@article{2e4569d9c0b941828b2f08cd66d6cabe,

title = "FLT3: ITDoes matter in leukemia",

abstract = "FMS-like tyrosine kinase-3 (FLT3), a receptor tyrosine kinase, is important for the development of the hematopoietic and immune systems. Activating mutations of FLT3 are now recognized as the most common molecular abnormality in acute myeloid leukemia, and FLT3 mutations may play a role in other hematologic malignancies as well. The poor prognosis of patients harboring these mutations renders FLT3 an obvious target of therapy. This review summarizes the data on the molecular biology and clinical impact of FLT3 mutations, as well as the therapeutic potential of several small-molecule FLT3 inhibitors currently in development.",

keywords = "AML, FLT3, ITD, Receptor tyrosine kinase, Tyrosine kinase inhibitor",

author = "M. Levis and D. Small",

note = "Funding Information: This work was supported by grants from the NCI (1K08CA95600-01A1, ML; CA70970 and CA91177, DS), the Sidney Kimmel Foundation for Cancer Research (ML), The American Society of Clinical Onoclogy (ML) D.S. is the Douglas Kroll Research Foundation Translations/Researcher of the Leukemia and Lymphoma Society and The Children{\textquoteright}s Cancer Foundation (DS).",

year = "2003",

month = sep,

day = "1",

doi = "10.1038/sj.leu.2403099",

language = "English (US)",

volume = "17",

pages = "1738--1752",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "9",

}

TY - JOUR

T1 - FLT3

T2 - ITDoes matter in leukemia

AU - Levis, M.

AU - Small, D.

N1 - Funding Information: This work was supported by grants from the NCI (1K08CA95600-01A1, ML; CA70970 and CA91177, DS), the Sidney Kimmel Foundation for Cancer Research (ML), The American Society of Clinical Onoclogy (ML) D.S. is the Douglas Kroll Research Foundation Translations/Researcher of the Leukemia and Lymphoma Society and The Children’s Cancer Foundation (DS).

PY - 2003/9/1

Y1 - 2003/9/1

N2 - FMS-like tyrosine kinase-3 (FLT3), a receptor tyrosine kinase, is important for the development of the hematopoietic and immune systems. Activating mutations of FLT3 are now recognized as the most common molecular abnormality in acute myeloid leukemia, and FLT3 mutations may play a role in other hematologic malignancies as well. The poor prognosis of patients harboring these mutations renders FLT3 an obvious target of therapy. This review summarizes the data on the molecular biology and clinical impact of FLT3 mutations, as well as the therapeutic potential of several small-molecule FLT3 inhibitors currently in development.

AB - FMS-like tyrosine kinase-3 (FLT3), a receptor tyrosine kinase, is important for the development of the hematopoietic and immune systems. Activating mutations of FLT3 are now recognized as the most common molecular abnormality in acute myeloid leukemia, and FLT3 mutations may play a role in other hematologic malignancies as well. The poor prognosis of patients harboring these mutations renders FLT3 an obvious target of therapy. This review summarizes the data on the molecular biology and clinical impact of FLT3 mutations, as well as the therapeutic potential of several small-molecule FLT3 inhibitors currently in development.

KW - AML

KW - FLT3

KW - ITD

KW - Receptor tyrosine kinase

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=0141836914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141836914&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2403099

DO - 10.1038/sj.leu.2403099

M3 - Review article

C2 - 12970773

AN - SCOPUS:0141836914

SN - 0887-6924

VL - 17

SP - 1738

EP - 1752

JO - Leukemia

JF - Leukemia

IS - 9

ER -

FLT3: ITDoes matter in leukemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this